Vor Biopharma Inc. (NASDAQ:VOR) Financings
Financings
| Raise | Date |
|---|---|
| At-the-market programme of at-the-market sales Closed: US$48.4M raised | Aug 11, 2026 |
| Private placement of common stock Announced: about US$150M · US$10.81 a share Buyers: RA Capital Management; Forbion (granted the right to appoint one director to the board); Frazier Life Sciences; Caligan Partners; Logos Capital; Venrock Healthcare Capital Partners Use of proceeds: Clinical development of telitacicept, including Phase 3 trials in myasthenia gravis and primary Sjögren's disease, plus working capital and general corporate purposes | Dec 15, 2025 |
| Public offering of shares Update: US$115M · US$10 a share · J.P. Morgan +3 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Citigroup (co-lead), TD Cowen (co-lead) | Nov 13, 2025 |
| Private placement of prefunded warrants Announced: about US$175M · US$0.25 a share · Warrants at US$0.0001 Buyers: RA Capital Management (existing stockholder); Mingxin Capital; Forbion; Venrock Healthcare Capital Partners; Caligan Partners; NEXTBio Use of proceeds: To advance development of its clinical pipeline and for general corporate purposes | Jun 25, 2025 |
| Private placement of shares of common stock and accompanying warrants Announced: about US$55.6M · US$0.9943 a share · Warrants at US$0.838 · Stifel Dealers: Stifel (lead) Buyers: Reid Hoffman (led the PIPE as new investor; granted one board seat and one board observer seat); RA Capital Management (existing investor and largest stockholder; participated) Use of proceeds: Fund clinical and preclinical development of its pipeline candidates and general corporate purposes | Dec 27, 2024 |